Updated:
iBio
iBio is a South San Francisco-based biotechnology company developing therapeutics for oncology and fibrosis using its proprietary protein platform.
iBio
iBio is a biotechnology company headquartered in South San Francisco, California, focused on developing therapeutic candidates for oncology and fibrosis. The firm's proprietary platform is designed to produce protein-based therapeutics with enhanced stability and manufacturability. The firm's strategy combines internal drug development with strategic partnerships, targeting multiple indications including solid tumors and fibrotic diseases. iBio's pipeline includes programs in preclinical and clinical stages, with a lead candidate in Phase 1/2 trials for solid tumors. The company has disclosed collaboration agreements with academic institutions and contract research organizations to advance its pipeline. Its geographic focus remains primarily North America, though it has engaged with partners globally. iBio's team size and deployment figures are not publicly disclosed, and no additional offices beyond South San Francisco have been confirmed. The firm maintains a focus on biotech R&D without publicly identifiable philanthropic structures or adjacent investment vehicles. As of the most recent public filings, the company continues to prioritize its clinical-stage pipeline development, with no major corporate events reported in the last 24 months beyond routine SEC filings. The structural differentiator for iBio is its identity as a development-stage biotech firm rather than a multi-asset family office, which sets it apart from traditional capital allocators. Its operations are oriented toward therapeutic discovery and early-stage clinical development, with governance and succession structures not publicly detailed due to its public company status.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Sector focus
Frequently asked questions
What is iBio's primary business focus?
iBio is a biotechnology company focused on developing novel protein-based therapeutics, primarily for oncology and fibrotic diseases. It operates a proprietary platform designed to produce stable therapeutic candidates with improved manufacturability (per the firm's SEC filings).
Who manages investment decisions at iBio?
iBio's management team is not publicly detailed in available sources. The company's public filings indicate governance through its board of directors and executive officers, but specific individuals responsible for capital allocation are not named in this analysis.
Does iBio invest in external companies or funds?
No — iBio is structured as a development-stage biotechnology company, not an investment firm. Its capital is deployed primarily into internal R&D programs, clinical trials, and collaborative partnerships with academic institutions and contract research organizations.
What therapeutic areas does iBio target?
iBio's pipeline includes candidates for solid tumors and fibrotic diseases. Its lead program targets a specific oncology indication, with additional preclinical programs exploring other cancer types and fibrotic conditions (per the firm's SEC filings and press releases).
Is iBio a public or private company?
iBio is a publicly traded company, listed on the NYSE American under the ticker symbol IBIO. This public structure differentiates it from traditional privately held family offices, as its operations and financials are subject to SEC disclosure requirements.
How does iBio source its therapeutic candidates?
iBio's candidates are developed internally using its proprietary protein engineering and expression platform. The company has also entered into collaborative research agreements with academic institutions to expand its pipeline, though specific deal flow sources are not extensively detailed in public filings.
Does iBio maintain philanthropic or charitable structures?
No philanthropic or charitable structures have been publicly identified for iBio. As a publicly traded biotechnology company, its focus remains on therapeutic development and shareholder value, without separate disclosed charitable arms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: